Fig. 3: Effects of the D2/D3 partial agonist aripiprazole on human-motivated behaviour, hedonic and emotional responses, motor function and reward processing.
From: Striatal dopamine D2/D3 receptor regulation of human reward processing and behaviour
A Effect of aripiprazole vs placebo on negative symptoms (Brief Negative Symptom Scale, individual values with mean ± SE). n = 27, linear mixed effects model: BNSS: b = 1.24, t(48) = 1.69, 95% CI = −0.24:2.72, two-sided p = 0.10. B Effect of aripiprazole vs placebo on akathisia (Barnes Akathisia Rating Scale, individual values with mean ± SE). n = 27, linear mixed effects model: b = 1.04, t(49) = 3.31, 95% CI = 0.41:1.67, two-sided p = 0.0017. C Effect of aripiprazole vs placebo on parkinsonism (Simpson Angus Scale, individual values with mean ± SE). n = 27, linear mixed effects model: b = 1.19, t(48) = 3.61, 95% CI = 0.53:1.85, two-sided p = 0.00073. D Effect of aripiprazole vs placebo on caudate activation during reward outcome in monetary incentive delay (MID) task (individual values with mean ± SE of beta values). n = 22, paired sample t-test: mean difference = 26.8, t(21) = 0.62, 95% CI = −116.4:62.7, FDR corrected two-sided p = 0.54. Source data are provided as a Source data file.
